PUBLICATIONS

• Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils, Carin A. Uyl-de Groot, Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands, Value in Health, 2024,
  https://doi.org/10.1016/j.jval.2024.06.003
• Heine RJSD, Thielen FW, Mathijssen RHJ, van Leeuwen RWF, Franken MG, et al. (2024) Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLOS ONE 19(2): e0293264. https://doi.org/10.1371/journal.pone.0293264

BROCHURE

Click here to read the project brochure

NEWSLETTER

Newsletter 01 – September 2023

Newsletter 02 – March 2024

Newsletter 03 – September 2024

POSTER

• B.P. Geisler, S. Meltzer, E.A. Burger, E. Aas, A.H.Ree: Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). Annals of Oncology 35:S936-S937 DOI: 10.1016/j.annonc.2024.08.1599 https://www.annalsofoncology.org/article/S0923-7534(24)03118-1/pdf
• B.P. Geisler, S. Meltzer, E.A. Burger, A.H. Ree, E. Aas: Cost-effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy. Abstract forthcoming in a Value in Health Supplement.
• Salcher-Konrad M, Hendrickx A, Schneider P, Zimmermann N. Defining fair prices for new health technologies. 5th PPRI conference 2024: Ensuring access to affordable medicines through innovative policies, Vienna, 25–26 April 2024
• Salcher-Konrad M, Zimmermann N, Schneider P, Hendrickx A: What is a fair price? A review of definitions for fair prices of health technologies. ISPOR Europe 2023, Copenhagen, 14 November 2023

WEBINARS

Basics of medicines pricing in Europe – March 2024

Greener pharmaceuticals: policies for an environmentally sustainable pharmaceutical system

press releases

Press Release 01

Press Release 02

OTHER 

• Interview for Dagens Medisin (news paper and trade magazine for Norwegian healthcare personnel and other employees within the healthcare sector): Camilla Ø. Ondrckova: “Nye, norske data kan føre til ny behandling for avansert tykktarmskreft” (in Norwegian) https://www.dagensmedisin.no/esmo-esmo-2024-forskning/nye-norske-data-kan-fore-til-ny-behandling-for-avansert-tykktarmskreft/651327
• Interview for Health Talk (website and video channel): «Er immunterapi mot tarmkreft kostnadseffektivt? Biomarkører kan være nøkkelen» (in English): https://www.healthtalk.no/tarmkreft/er-immunterapi-mot-tarmkreft-kostnadseffektivt-biomarkorer-kan-vaere-nokkelen/189801  (teaser)
• DM Arena Post ESMO (post-conference recap, organized by Dagens Medisin) https://www.dagensmedisin.no/dmarena/dm-arena-post-esmo-opptak-tilgjengelig-na/646377
• Vumedi video, summary of the ESMO talk https://www.vumedi.com/video/esmo-2024-insights-the-value-of-immune-checkpoint-blockade-in-msspmmr-mcrc/